Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 15/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5584385 | 1.00 | CCR1 (0.45) | CCR1HTR1ASLC6A4DRD4 | |
| SCHEMBL14571546 | 1.00 | CCR1 (0.45) | CCR1HTR1ASLC6A4DRD4 | |
| SCHEMBL5584254 | 1.00 | CCR1 (0.45) | CCR1HTR1ASLC6A4DRD4 | |
| Hydrochloric Acid SCHEMBL4763026 | 0.99 | CCR1 (0.44) | CCR1HTR1ASLC6A4DRD4 | |
| Hydrochloric Acid SCHEMBL21772205 | 0.99 | CCR1 (0.44) | CCR1HTR1ASLC6A4DRD4 | |
| Hydrochloric Acid SCHEMBL6803575 | 0.98 | CCR1 (0.44) | CCR1HTR1ASLC6A4DRD4 | |
| Hydrochloric Acid SCHEMBL5584636 | 0.98 | CCR1 (0.44) | CCR1HTR1ASLC6A4DRD4 | |
| SCHEMBL6209369 | 0.95 | CCR1 (0.45) | CCR1HTR1ASLC6A4DRD4 | |
| SCHEMBL14571641 | 0.95 | CCR1 (0.44) | CCR1HTR1ASLC6A4DRD4 | |
| Hydrochloric Acid SCHEMBL5584374 | 0.95 | CCR1 (0.44) | CCR1HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250228837-A1 | (2S)-1-[4-(3,4-DICHLOROPHENYL)PIPERIDIN-1-YL]-3-[2-(5-METHYL-1,3,4-OXADIAZOL-2-YL)BENZO[B]FURAN-4-YLOXY] PROPAN-2-OL OR ITS METABOLITE FOR TREATING ANXIETY DISORDERS | MINERVA NEUROSCIENCES, INC. | 2025-07-17 | — | — | US | disclosed |
| US-20250109127-A1 | METHODS OF USE OF PHENOXYPROPYLAMINE COMPOUNDS TO TREAT DEPRESSION | MINERVA NEUROSCIENCES, INC. | 2025-04-03 | — | — | US | disclosed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| CN-116981450-A | Combination of antidepressants and dextromethorphan for the treatment of neuropsychiatric disorders | 安泰赛普生物风投二代有限责任公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230248714-A1 | (2S)-1-[4-(3,4-DICHLOROPHENYL)PIPERIDIN-1-YL]-3-[2-(5-METHYL-1,3,4-OXADIAZOL-2-YL)BENZO[B]FURAN-4-YLOXY] PROPAN-2-OL OR ITS METABOLITE FOR TREATING ANXIETY DISORDERS | MINERVA NEUROSCIENCES, INC. | 2023-08-10 | — | — | US | disclosed |
| CN-114848641-A | Compounds or metabolites thereof for use in the treatment of anxiety disorders | 田边三菱制药株式会社 | 2022-08-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228837-A1 | (2S)-1-[4-(3,4-DICHLOROPHENYL)PIPERIDIN-1-YL]-3-[2-(5-METHYL-1,3,4-OXADIAZOL-2-YL)BENZO[B]FURAN-4-YLOXY] PROPAN-2-OL OR ITS METABOLITE FOR TREATING ANXIETY DISORDERS | HTR2C, HTR1D, HTR2A | CCR1 2201/4885HTR1A 9/4885SLC6A4 69/4885 |
| US-20230248714-A1 | (2S)-1-[4-(3,4-DICHLOROPHENYL)PIPERIDIN-1-YL]-3-[2-(5-METHYL-1,3,4-OXADIAZOL-2-YL)BENZO[B]FURAN-4-YLOXY] PROPAN-2-OL OR ITS METABOLITE FOR TREATING ANXIETY DISORDERS | HTR2C, HTR1D, HTR2A | CCR1 2201/4885HTR1A 9/4885SLC6A4 69/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | CCR1 1453/4885HTR1A 4/4885SLC6A4 30/4885 |
| US-20250109127-A1 | METHODS OF USE OF PHENOXYPROPYLAMINE COMPOUNDS TO TREAT DEPRESSION | HTR5A, HTR7, HTR6 | CCR1 2954/4885HTR1A 6/4885SLC6A4 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.